SynthesisBMC cancer2019
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
Synthesis in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it, 176 citations in OpenAlex.
- Prevalence of PICC-related thrombosis in patients with hematological malignancies: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Pooled it
- Telehealth-Delivered Dietary Counseling in Myeloproliferative Neoplasms: A Randomized Feasibility Study.Nutrients · 2026Trial
- Thrombotic burden and longitudinal outcomes in Thai patients with polycythemia vera.Annals of medicine · 2026Article
- Philadelphia-negative myeloproliferative neoplasms and acquired von Willebrand syndrome: only pertinent at diagnosis?Research and practice in thrombosis and haemostasis · 2026Article
- Clinical and prognostic significance of concomitant autoimmune disease in patients with myelofibrosis.Annals of hematology · 2026Article
- Monitoring of JAK2V617F allele burden in patients with essential thrombocythemia.Blood research · 2026Article
- Review
- Clonal Hematopoiesis and Incident Heart Failure.JAMA cardiology · 2026Article
- Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.Leukemia · 2026Article
- Outcomes of patients with myeloproliferative neoplasms and critical limb ischemia: insights from the National readmissions database.Journal of thrombosis and thrombolysis · 2025Article
- Contraception in Myeloproliferative Neoplasms: A Pharmacological Review.European journal of haematology · 2025Review
- Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms.Annals of hematology · 2025Article
- Prevalence of Arterial Stiffness Determined by Cardio-Ankle Vascular Index in Myeloproliferative Neoplasms.Journal of clinical medicine · 2025Article
- Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2025Review
- Thrombocytosis and bleeding in myeloproliferative neoplasms: exploring clinical diversity and risk of acquired von Willebrand syndrome-insights from a UK center.Research and practice in thrombosis and haemostasis · 2025Article
- Impact of age and time since diagnosis on thrombosis risk in myeloproliferative neoplasm patients: A nationwide register-based matched cohort study.British journal of haematology · 2025Article
- Acute Myocardial Infarction with Cardiogenic Shock and Subsequent Intracranial Hemorrhage in a 44-Year-Old Woman with Profound Thrombocythemia: A Case Report and Review of Literature.Acta Cardiologica Sinica · 2025Article
- The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients.Cancer research and treatment · 2025Article
- Article
- Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhiladelphia (Ph) chromosome-negative myeloproliferative neoplasms (MPNs) are a heterogeneous group of hematopoietic stem cell clonal diseases. Most patients with MPN are asymptomatic at diagnosis although some of them suffer from constitutional symptoms. Thrombosis and bleeding can also be one of the initial manifestations although the reported prevalence varied considerably across the studies. This systematic review and meta-analysis was conducted with the aims to better understand the prevalence and characteristics of thrombosis and bleeding among patients with newly-diagnosed MPN.
methodsUsing a search strategy that included the terms for myeloproliferative neoplasms, thrombosis, and bleeding, two investigators independently searched for published articles indexed in the MEDLINE and EMBASE databases from inception to August 2018. The pooled prevalence was calculated using the DerSimonian-Laird random-effects model with a double arcsine transformation.
resultsA total of 29 cohort studies (8 prospective and 21 retrospective) with 13,436 patients with MPN were included into this meta-analysis. At diagnosis, the pooled prevalence of overall thrombosis among patients with MPN was 20.0% (95% CI, 16.6-23.8%; I
conclusionsThrombosis and bleeding are common initial manifestations of MPN. Investigations for MPN should be considered for patients who present with unexplained thrombosis or abnormal bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.